CompletedPhase 1NCT06607380
A Randomized, Open-Label, Parallel-Design Pharmacokinetic and Pharmacodynamic Interaction Study of TNM002 and Adsorbed Tetanus Vaccine
Studying Tetanus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
- Principal Investigator
- Jie Hou, DoctorPeking University Care Luzhong Hospital
- Intervention
- TNM002(biological)
- Enrollment
- 60 enrolled
- Eligibility
- 18-55 years · All sexes
- Timeline
- 2022 – 2023
Study locations (1)
- PKUCare Luzhong Hospital, Zibo, Shandong, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06607380 on ClinicalTrials.govOther trials for Tetanus
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE1NCT07149454Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody InjectionLanzhou Institute of Biological Products Co., Ltd
- RECRUITINGNCT07107932A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following InjuryZhuhai Trinomab Pharmaceutical Co., Ltd.
- RECRUITINGPHASE3NCT06635798A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 InjectionGenrix (Shanghai) Biopharmaceutical Co., Ltd.